Clinical trial
Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK…
NCT00390143 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00390143 |
|---|---|
| Title | Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612 |
| Official title | Assess Long Term Persistence of a Primary Dose of GSK Biologicals' Meningococcal Vaccine 134612 Versus One Dose of Mencevax™ ACWY in Healthy Adolescents/Young Adults (15 to 19 Years at Vaccination) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infections, Meningococcal |
| Intervention type | Biological |
| Interventions | Meningococcal vaccine 134612, Mencevax™ ACWY |
| Enrollment | 46 |
| Start date | Feb 1, 2007 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Oct 19, 2006 |
| Last update posted | Oct 25, 2016 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: